title: Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines.
abstract: α-Galactosylceramide (α-GalCer) represents a new class of immune stimulators and vaccine adjuvants that activate type I natural killer T (NKT) cells to swiftly release cytokines and to exert helper functions for acquired immune responses. This unique property prompted clinicians to exploit the antitumor potential of NKT cells. Here, we review the effects of α-GalCer in (pre)clinics and discuss current and future strategies that aim to optimize NKT cell-mediated antitumor therapy, with a particular focus on cell-based and nanovector vaccines.
authors.affiliation: Authors' Affiliations: Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille; Institut National de la Santé et de la Recherche Médicale; Centre National de la Recherche Scientifique, UMR 8204; Université Lille Nord de France; Institut Fédératif de Recherche 142, Lille, France.
authors.forename: C
authors.initials: C
authors.lastname: Faveeuw
authors.forename: F
authors.initials: F
authors.lastname: Trottein
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage*; D005699:Galactosylceramides / Q000008:administration & dosage; D006801:Humans; D007113:Immunity, Innate; D007167:Immunotherapy; D053769:Nanocapsules; D055611:Natural Killer T-Cells / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D005699:Galactosylceramides; D053769:Nanocapsules; C493154:alpha-galactosylceramide